Dapsone in the Management of Autoimmune Bullous Diseases

Piette, Evan W.; Werth, Victoria P.

doi:10.1016/j.det.2011.06.018

Cited by 30 publications

(17 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, dapsone has anti-inflammatory properties like non-steroidal antiinflammatory drugs. Dapsone suppresses neutrophilic infiltration by inhibition of neutrophil activation and recruitment through many different pathways [39].…”

Section: Dapsonementioning

confidence: 99%

Current Therapy in Autoimmune Bullous Diseases

Svecova¹

2018

Autoimmune Bullous Diseases

View full text Add to dashboard Cite

The goal of the treatment of autoimmune bullous disease is to reduce the production of pathogenic autoantibodies or increase elimination of pathogenic autoantibodies from serum of the patients. Immunosuppressive therapy reduces the production of autoantibodies. The therapy protocol is divided into three phases. The first is a control phase with the highest dose of immunosuppressive drugs suppressing activity of disease, followed with a consolidation phase, when the bulk of lesions is healed. The last phase is a maintenance phase when immunosuppressive medication is gradually tapered to the lowest level that suppresses the appearance of new lesions. In complete remission off therapy, the patient reached complete clinical remission and does not use any immunosuppressive medication. In complete remission on therapy, the patient uses a minimal immunosuppressive therapy. The first-line treatment is corticosteroids in pemphigus and pemphigoid groups. Adjuvant immunosuppressive drugs are combined with systemic corticosteroids and display a corticosteroid sparing effect. First-line immunosuppressive adjuvants comprise azathioprine, mycophenolate mofetil and mycophenolic acid. Rituximab, intravenous immunoglobulin G, immunoadsorption, cyclophosphamide, dapsone, and methotrexate are regarded as the second-line adjuvants. In dermatitis herpetiformis, a gluten free diet eliminates the clinical symptoms. Dapsone is regarded to be a valid therapeutic option in management of dermatitis herpetiformis.

show abstract

Section: Dapsonementioning

confidence: 99%

Current Therapy in Autoimmune Bullous Diseases

Svecova¹

2018

Autoimmune Bullous Diseases

View full text Add to dashboard Cite

show abstract

“…In addition, dapsone is used in a number of dermatoses with neutrophilic and eosinophilic involvement. The main indications include blistering skin diseases such as Duhring disease, pemphigus vulgaris, bullous pemphigoid, linear IgA dermatosis, as well as bullous and mucocutaneous forms of lupus erythematosus [6,[10][11][12]. Dapsone is also used in infantile acropustulosis, erythema elevatum diutinum, prurigo pigmentosa, Sneddon-Wilkinson disease, lichen planus, pustular psoriasis, pyoderma gangrenosum, Sweet syndrome, as well as on a case-by-case basis to treat granuloma annulare, pressure urticaria, and urticarial vasculitis [9,13].…”

Section: Clinical Lettermentioning

confidence: 99%

Asymptomatic dapsone‐induced agranulocytosis in a patient with chronic spontaneous urticaria

Milkova¹,

Hallermann²,

Simon³

et al. 2014

J Deutsche Derma Gesell

View full text Add to dashboard Cite

“…Dapsone has been used in mucocutaneous diseases (Piette and Werth, 2012) and is the drug of choice for treatment of dermatitis herpetiformis. A small randomized control trial (Werth et al, 2008) and few case reports of patients exist in the literature evaluating patients with pemphigus vulgaris (PV; including patients with oral lesions).…”

Section: Applications Of Dapsone In Oral Diseasesmentioning

confidence: 99%

“…A small randomized control trial (Werth et al, 2008) and few case reports of patients exist in the literature evaluating patients with pemphigus vulgaris (PV; including patients with oral lesions). (Piette and Werth, 2011). Dapsone was used in combination with corticosteroids, and although improvements were reported, no definite conclusions could be drawn on the efficacy of dapsone for PV (Martin et al, 2011).…”

Section: Applications Of Dapsone In Oral Diseasesmentioning

confidence: 99%

Systemic use of non‐biologic agents in orofacial diseases: other immunomodulatory agents

Georgakopoulou

Scully²

2013

Oral Diseases

View full text Add to dashboard Cite

Systemic non-biologic agents have long been in clinical use in medicine -often with considerable efficacy, albeit with some adverse effects -as with all medications. With the advent of biologic agents, all of which currently are restricted to systemic use, there is a growing need to ensure which agents have the better therapeutic ratio. The non-biologic agents (NBAs) include a range of agents, most importantly the corticosteroids (steroids). Previous articles by us in this series have discussed systemic use of corticosteroids and purine synthesis inhibitors; the other immunomodulating agents (calcineurin inhibitors, thalidomide, dapsone, colchicine and cyclophosphamide) are reviewed in this final article.

show abstract

Dapsone in the Management of Autoimmune Bullous Diseases

Cited by 30 publications

References 39 publications

Current Therapy in Autoimmune Bullous Diseases

Current Therapy in Autoimmune Bullous Diseases

Asymptomatic dapsone‐induced agranulocytosis in a patient with chronic spontaneous urticaria

Systemic use of non‐biologic agents in orofacial diseases: other immunomodulatory agents

Contact Info

Product

Resources

About